At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Montanide ISA 51 VG, and 3 other interventions for Glioblastoma and Gliosarcoma. Active but no longer recruiting, targeting 66 participants across 5 sites.
Detailed Summary
This phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to kill tumor cells that express survivin. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without vaccine therapy in treating glioblastoma.
Study Details
Timeline
Interventions
Correlative studies
Given SC
Given SC
Given SC
Given PO or IV